Document is current
Any future updates will be listed below
-
Authors
Choudhary, Manish C.
Chew, Kara W. https://orcid.org/0000-0003-4865-4348
Deo, Rinki
Flynn, James P.
Regan, James https://orcid.org/0000-0003-0449-2295
Crain, Charles R.
Moser, Carlee https://orcid.org/0000-0001-5601-9112
Hughes, Michael D.
Ritz, Justin https://orcid.org/0000-0001-6307-4849
Ribeiro, Ruy M. https://orcid.org/0000-0002-3988-8241
Ke, Ruian https://orcid.org/0000-0001-5307-8934
Dragavon, Joan A.
Javan, Arzhang Cyrus
Nirula, Ajay
Klekotka, Paul
Greninger, Alexander L.
Fletcher, Courtney V. https://orcid.org/0000-0002-3703-7849
Daar, Eric S.
Wohl, David A. https://orcid.org/0000-0002-7764-0212
Eron, Joseph J.
Currier, Judith S. https://orcid.org/0000-0003-4279-4737
Parikh, Urvi M.
Sieg, Scott F. https://orcid.org/0000-0002-1769-8682
Perelson, Alan S. https://orcid.org/0000-0002-2455-0002
Coombs, Robert W. https://orcid.org/0000-0003-2709-0512
Smith, Davey M. https://orcid.org/0000-0003-3603-1733
Li, Jonathan Z. https://orcid.org/0000-0001-9914-9662
,
Smith, David
Javan, Arzhang Cyrus
Giganti, Mark
Hosey, Lara
Roa, Jhoanna
Patel, Nilam
Colsh, Kelly
Rwakazina, Irene
Beck, Justine
Sieg, Scott
Fischer, William
Evering, Teresa
Ignacio, Rachel Bender
Cardoso, Sandra
Corado, Katya
Jagannathan, Prasanna
Jilg, Nikolaus
Pillay, Sandy
Riviere, Cynthia
Singh, Upinder
Taiwo, Babafemi
Gottesman, Joan
Newell, Matthew
Pedersen, Susan
Dragavon, Joan
Jennings, Cheryl
Greenfelder, Brian
Murtaugh, William
Kosmyna, Jan
Gapara, Morgan
Shahkolahi, Akbar
- License Information
-
More Information
Article History
Received: 15 September 2021
Accepted: 19 September 2022
First Online: 26 October 2022
Competing interests
: KWC received research funding to the institution from Merck Sharp & Dohme and is a consultant for Pardes Biosciences. ESD receives consulting fees from Gilead Sciences, Merck and GSK/ViiV and research support through the institution from Gilead Sciences and GSK/ViiV. DAW received funding to the institution to support research and honoraria for advisory boards and consulting from Gilead Sciences. JZL has consulted for Abbvie. C. ALG reports contract testing from Abbott and research support from Merck and Gilead. PK, and AN are employees and shareholders of Eli Lilly. JJE is an ad hoc consultant to GSK/VIR, data monitoring committee (DMC) chair for Adagio Phase III studies. JSC has consulted for Merck and Company. DMS consulted for the following companies Fluxergy, Kiadis, Linear Therapies, Matrix BioMed, Arena Pharmaceuticals, VxBiosciences, Model Medicines, Bayer Pharmaceuticals, Signant Health and Brio Clinical. PK and AN are employees and shareholders of Eli Lilly. All other authors (MCC, RD, JPF, JRegan, CRC, MDH, JRitz, RMR, RK, JAD, ACJ, CVF, UMP, SFS, ASP, RWC) report no competing interests.
Free to read: This content has been made available to all.
